These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34690091)

  • 21. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
    Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
    N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
    Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
    Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
    Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
    Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.
    Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Yim SH; Kim HJ; Kwon YR; Jeon YW; Lee SH; Chung YJ; Lee JH
    Leuk Res; 2018 Nov; 74():97-104. PubMed ID: 30343213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
    DiGennaro J; Sallman DA
    Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
    Ren Y; Wang J; Zhang H; Mei C; Ye L; Luo Y; Zhou X; Zhu S; Jiang L; Wang L; Jin J; Tong H
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):172-179. PubMed ID: 32030889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
    Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.
    Hunter AM; Komrokji RS; Yun S; Al Ali N; Chan O; Song J; Hussaini M; Talati C; Sweet KL; Lancet JE; Padron E; List AF; Sallman DA
    Blood Adv; 2021 Feb; 5(4):1017-1028. PubMed ID: 33591325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
    Caballero JC; Sánchez Barba M; Hernández Sánchez JM; Such E; Janusz K; Sanz G; Cabrero M; Chillón C; Cervera J; Hurtado AM; Jerez A; Calderón Cabrera C; Valcárcel D; Lumbreras E; Abáigar M; López Cadenas F; Hernández Rivas JM; Del Cañizo MC; Díez Campelo M
    Ann Hematol; 2019 Sep; 98(9):2151-2162. PubMed ID: 31312927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes and characteristics of patients with
    Bewersdorf JP; Shallis RM; Gowda L; Wei W; Hager K; Isufi I; Kim TK; Pillai MM; Seropian S; Podoltsev NA; Gore SD; Siddon AJ; Zeidan AM
    Leuk Lymphoma; 2020 Sep; 61(9):2180-2190. PubMed ID: 32362171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute Myeloid Leukemia and Myelodysplastic Syndromes with
    Sill H; Zebisch A; Haase D
    Clin Cancer Res; 2020 Oct; 26(20):5304-5309. PubMed ID: 32816950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of
    Shen K; Hu DY; Chen SN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):811-818. PubMed ID: 38926972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinico-genomic profiling and clonal dynamic modeling of
    Patel SA; Lloyd MR; Cerny J; Shi Q; Simin K; Ediriwickrema A; Hutchinson L; Miron PM; Higgins AW; Ramanathan M; Gerber JM
    Leuk Lymphoma; 2021 Dec; 62(14):3348-3360. PubMed ID: 34496723
    [No Abstract]   [Full Text] [Related]  

  • 35. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
    Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
    Nat Med; 2020 Oct; 26(10):1549-1556. PubMed ID: 32747829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
    Chen Y; Zheng J; Weng Y; Wu Z; Luo X; Qiu Y; Lin Y; Hu J; Wu Y
    Ann Hematol; 2024 Apr; 103(4):1211-1220. PubMed ID: 38409598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.
    Yan X; Wang L; Jiang L; Luo Y; Lin P; Yang W; Ren Y; Ma L; Zhou X; Mei C; Ye L; Xu G; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Med; 2021 Mar; 10(5):1759-1771. PubMed ID: 33609081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.